Talk:Retigabine
Latest comment: 11 years ago by Wzrd1 in topic Added in adverse reaction warned in today's FDA drug safety communication
This is the talk page for discussing improvements to the Retigabine article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Retigabine.
|
A fact from Retigabine appeared on Wikipedia's Main Page in the Did you know column on 1 August 2010 (check views). The text of the entry was as follows:
|
This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||
|
Europe
editHi - it would be helpful if someone would summarise the history of this compound with respect to the European Medicines Agency's review and approval. As it reads now, it seems like it's a US-only drug, whereas it was approved in Europe first and there's useful information from the EMA as to the product. Thanks. — Preceding unsigned comment added by PetePharm (talk • contribs) 11:51, 14 June 2011 (UTC)
- Yes, that's a fair point. Will try to add some info later today. Fvasconcellos (t·c) 14:02, 14 June 2011 (UTC)
Added in adverse reaction warned in today's FDA drug safety communication
editCame in today's e-mail batch from the FDA mailing list.Wzrd1 (talk) 23:41, 26 April 2013 (UTC)